Novartis has announced that its investigational antisense oligonucleotide pelacarsen failed to meet the primary endpoint in the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial, according to a corporate update. The study evaluated the drug’s efficacy in reducing major adverse cardiovascular events among patients with elevated lipoprotein(a) levels and established cardiovascular disease.
Lp(a)HORIZON Trial Design and Results
The clinical trial enrolled over 8,000 patients with elevated lipoprotein(a) levels at or above 70 nmol/L who had already experienced a prior cardiovascular event, according to trial disclosures. Despite successfully lowering lipoprotein(a) levels by approximately 80%, pelacarsen did not demonstrate a statistically significant reduction in the composite endpoint of cardiovascular death, myocardial infarction, or urgent coronary revascularization when compared to a placebo.
Lipoprotein(a) is widely recognized as a genetically determined, independent risk factor for cardiovascular disease, affecting roughly 20% of the global population. Because these levels are largely dictated by genetics rather than lifestyle choices or traditional lipid-lowering therapies, the pharmaceutical industry has invested heavily in targeted RNA-based reduction strategies, with pelacarsen serving as the most clinically advanced candidate in the class.
Industry Impact on RNA Therapeutics and Manufacturing
The negative outcome of the Lp(a)HORIZON trial marks the third major cardiovascular outcomes trial disappointment in a two-month span, creating broader uncertainty across the cardio-metabolic drug development sector. Competing pharmaceutical companies developing alternative RNA-based treatments, such as Amgen with olpasiran and Eli Lilly with lepodisiran, now face renewed scrutiny regarding whether their respective mechanisms can achieve clinical benefit where pelacarsen fell short.
Supply chain and manufacturing sectors tied to antisense oligonucleotides also face immediate recalibration. Companies supplying specialized active pharmaceutical ingredients and intermediates for antisense oligonucleotide synthesis must evaluate potential shifts in demand as developers reassess clinical pipelines, though the continued advancement of alternative programs sustains long-term interest in specialized nucleotide chemistry.
Next Steps for Novartis and the Pelacarsen Program
Novartis stated that it plans to conduct comprehensive subgroup and biomarker analyses of the Lp(a)HORIZON dataset to determine the underlying reasons for the disconnect between biomarker reduction and clinical outcomes. These upcoming evaluations will guide corporate decision-making regarding the future trajectory of the pelacarsen clinical development program.
